Extended Data Fig. 2: Kaplan-Meier curves of progression-free survival and duration of response. | Nature Medicine

Extended Data Fig. 2: Kaplan-Meier curves of progression-free survival and duration of response.

From: Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial

Extended Data Fig. 2

a, Progression-free survival (PFS) of patients in the efficacy population. b, Duration of response (DOR) of patients in the efficacy population who had a partial or complete response. PFS, DOR and the corresponding 2-sided 95% confidence interval (CI) were estimated by the Kaplan-Meier method. CI = confidence interval; NE = not estimable.

Back to article page